Advisornet Financial’s Vaxcyte PCVX Stock Holding History

Advisornet Financial’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-6	Closed	-$216	–	2330
2025 Q3	$216	Sell	6 -85	-93%	-$2.82K	﹤0.01%	2155
2025 Q2	$2.96K	Buy	91 +86	+1,720%	+$2.82K	﹤0.01%	1771
2025 Q1	$189	Sell	5 -2	-29%	-$160	﹤0.01%	2079
2024 Q4	$573	Buy	+7	New	+$695	﹤0.01%	1747

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Advisornet Financial's PCVX Position: Q4 2025 in Review

Advisornet Financial sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 6 shares — an estimated $216 sold.

Advisornet Financial first reported a position in PCVX in Q4 2024 and held it in 4 quarters. The position peaked at $2.96K in Q2 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

Advisornet Financial reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
Advisornet Financial sold 6 Vaxcyte shares in Q4 2025, an estimated $216.
Advisornet Financial first reported a position in Vaxcyte in Q4 2024 and held it in 4 quarters.
Advisornet Financial's Vaxcyte position peaked at $2.96K in Q2 2025.
295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Advisornet Financial's 13F filing for Q4 2025, filed 20 Jan 2026.